Ventana Biotech, Inc.
VNTA
Rank in Stocks
#33940
Ventana Biotech, Inc. is an emerging biotechnology enterprise focused on the... Ventana Biotech, Inc. is an emerging biotechnology enterprise focused on the lifecycle of drug candidates for personalized medicine, encompassing the identification, assessment, acquisition, development, and eventual commercialization through partnerships of relevant intellectual property. The company's primary therapeutic area is addressing obesity and its associated medical conditions. Notably, Ventana holds proprietary rights to a medicated chewing gum formulation that integrates an extract of hoodia gordonii and 2-hydroxyoleic acid. This unique composition is intended for the management of obesity, hypertension, and various other metabolic disorders. Ventana is actively engaged in developing these appetite-suppressant chewing gums into distinct products: a lower-dosage version aimed at the over-the-counter market, and a higher-dosage variant slated for distribution via pharmacists. The lower-strength product is expected to be retailed in drugstores and health food establishments. Established in 1989, Ventana Biotech, Inc. operates from Butschwil, Switzerland. The company adopted its current name in October 2008, having previously been known as Personalica, Inc.
Share Price
$0.049
Last synced: 2026-11-06
Market Cap
$134.91K
Change (1 day)
55.06%
Change (1 year)
1.87%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Ventana Biotech, Inc. (VNTA)
Category
Financial Services
Operating Margin for Ventana Biotech, Inc. (VNTA)
Operating Margin as of November 2026 TTM: 87.99%
According to Ventana Biotech, Inc.'s latest financial reports, its current operating margin (TTM) is 87.99%. At the end of 2025 the company had an operating margin of 87.99%.
Operating Margin history for Ventana Biotech, Inc. from 2008 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 87.99% | 0.00% |
| 2025 | 87.99% | 75.00% |
| 2024 | 50.28% | -13.28% |
| 2023 | 57.98% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 0.00% | -100.00% |
US
|
|
| 9.21% | -99.90% |
US
|
|
| -2,061.14% | -123.42% |
CN
|
|
| 2.14% | -99.98% |
US
|
|
| -20,955.80% | -338.16% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Ventana Biotech, Inc.'s operating margin
What is Ventana Biotech, Inc.'s operating margin?
Ventana Biotech, Inc.'s operating margin is 87.99%, as of Nov 2026.
What was Ventana Biotech, Inc.'s operating margin in 2025?
In 2025, Ventana Biotech, Inc.'s operating margin was 87.99%, compared with 50.28% in 2024.
How has Ventana Biotech, Inc.'s operating margin changed since 2021?
From 2021 to 2025, Ventana Biotech, Inc.'s operating margin was highest in 2025 (87.99%) and lowest in 2021 (0.00%).
How does Ventana Biotech, Inc.'s operating margin compare with similar companies?
Ventana Biotech, Inc.'s operating margin (87.99%) is higher than that of all 5 similar companies listed above. The highest among them is Worldwide Webb Acquisition Corp., with 9.21%.